Gilead’s $300M deal with Dragonfly builds on 2022’s NK cell momentum

NK cells have been a bright spot for biotech in 2022, and Gilead is the latest company to buy into the technology through a $300 million research collaboration with Dragonfly to access candidates emerging from its NK cell engager platform.

Through the deal, Gilead Sciences Inc. (NASDAQ:GILD) gained an exclusive license to DF7001, a preclinical Tri-specific NK Engager (TriNKET) targeting oncofetal antigen 5T4, plus options to additional NK cell engager programs for $300 million up front, milestones and up to 20% royalties on sales. ...